Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

This study has suspended participant recruitment.
(Drug shortage)
Sponsor:
Collaborators:
National Cancer Institute (NCI)
AEterna Zentaris
Information provided by (Responsible Party):
University of Southern California
ClinicalTrials.gov Identifier:
NCT01240629
First received: June 30, 2010
Last updated: April 6, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: November 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)